PD-1 combination therapy with IL-2 modifies CD8 + T cell exhaustion program
Masao Hashimoto,Koichi Araki,Maria A. Cardenas,Peng Li,Rohit R. Jadhav,Haydn T. Kissick,William H. Hudson,Donald J. McGuire,Rebecca C. Obeng,Andreas Wieland,Judong Lee,Daniel T. McManus,James L. Ross,Se Jin Im,Junghwa Lee,Jian-Xin Lin,Bin Hu,Erin E. West,Christopher D. Scharer,Gordon J. Freeman,Arlene H. Sharpe,Suresh S. Ramalingam,Alex Pellerin,Volker Teichgräber,William J. Greenleaf,Christian Klein,Jorg J. Goronzy,Pablo Umaña,Warren J. Leonard,Kendall A. Smith,Rafi Ahmed
DOI: https://doi.org/10.1038/s41586-022-05257-0
IF: 64.8
2022-09-29
Nature
Abstract:Combination therapy with PD-1 blockade and IL-2 is highly effective during chronic lymphocytic choriomeningitis virus infection 1 . Here we examine the underlying basis for this synergy. We show that PD-1 + IL-2 combination therapy, in contrast to PD-1 monotherapy, substantially changes the differentiation program of the PD-1 + TCF1 + stem-like CD8 + T cells and results in the generation of transcriptionally and epigenetically distinct effector CD8 + T cells that resemble highly functional effector CD8 + T cells seen after an acute viral infection. The generation of these qualitatively superior CD8 + T cells that mediate viral control underlies the synergy between PD-1 and IL-2. Our results show that the PD-1 + TCF1 + stem-like CD8 + T cells, also referred to as precursors of exhausted CD8 + T cells, are not fate-locked into the exhaustion program and their differentiation trajectory can be changed by IL-2 signals. These virus-specific effector CD8 + T cells emerging from the stem-like CD8 + T cells after combination therapy expressed increased levels of the high-affinity IL-2 trimeric (CD25–CD122–CD132) receptor. This was not seen after PD-1 blockade alone. Finally, we show that CD25 engagement with IL-2 has an important role in the observed synergy between IL-2 cytokine and PD-1 blockade. Either blocking CD25 with an antibody or using a mutated version of IL-2 that does not bind to CD25 but still binds to CD122 and CD132 almost completely abrogated the synergistic effects observed after PD-1 + IL-2 combination therapy. There is considerable interest in PD-1 + IL-2 combination therapy for patients with cancer 2,3 , and our fundamental studies defining the underlying mechanisms of how IL-2 synergizes with PD-1 blockade should inform these human translational studies.
multidisciplinary sciences